<p>Arch Biopartners Inc. released its consolidated financial statements for the full year ended September 30, 2025. The company reported cash and cash equivalents of USD 2.1 thousand at the end of the period. Cash flow from financing activities totaled USD 1.6 million for the year, including proceeds from share capital issuance of USD 1.2 million and advances from shareholders of USD 0.3 million. The company’s financial statements were prepared in accordance with International Financial Reporting Standards. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arch Biopartners Inc. published the original content used to generate this news brief on January 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

SBIO

ARTH

HBIO

<p>Arch Biopartners Inc. reported a net loss of USD 1.6 million for the fiscal year ending September 30, 2025. The company had cash and cash equivalents of USD 2.1 thousand at the end of the period. Cash flow from financing activities was USD 1.6 million, which included USD 1.2 million from share capital issuance and USD 0.3 million from shareholder advances. The financial statements were prepared in accordance with International Financial Reporting Standards.</p>

Reuters

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Arch Therapeutics, Inc.

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Harvard Bioscience

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Arch Biopartners posts FY net loss of USD 1.6 million and cash flow from financing activities of USD 1.6 million